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Abstract
Purpose Necroptosis has been proposed as a mode of cell
death that is a caspase-independent programmed necrosis.
We investigated whether necroptosis is involved in myo-
cardial ischemia–reperfusion injury in isolated guinea pig
hearts and, if so, whether simultaneous inhibition of nec-
roptosis and apoptosis confers enhanced cardioprotection.
Methods Isolated perfused guinea pig hearts were sub-
jected to 30 min ischemia and 4 h reperfusion (con-
trol = CTL, n = 8). Necrostatin-1 (necroptosis inhibitor,
10 lM), Z-VAD (apoptosis inhibitor, 0.1 lM) and both
inhibitors were administered starting 5 min before ische-
mia and during the initial 30 min of reperfusion (Nec,
Z-VAD, Nec ? Z-VAD; n = 8 each). Contractile recovery
was monitored by left ventricular developed (LVDP) and
end-diastolic (LVEDP) pressure. Infarct size was deter-
mined by triphenyltetrazolium chloride staining. Tissue
samples were obtained after 4 h reperfusion to determine
expression of receptor-interacting protein 1 (RIP1) and
activated caspase 3 by Western blot analysis.
Results After reperfusion, Nec ? Z-VAD had higher
LVDP and lower LVEDP compared with CTL. Infarct size
was reduced in Nec and Z-VAD compared with CTL.
Combination of necroptosis and apoptosis inhibition fur-
ther reduced infarct size. Expression of activated caspase 3
was not increased in Z-VAD and Nec ? Z-VAD compared
with Nec and CTL. Expression of RIP1 was preserved in
Z-VAD and Nec ? Z-VAD compared with CTL, sug-
gesting RIP1-mediated necrosis is involved in myocardial
ischemia–reperfusion injury.
Conclusion Necroptosis is involved in myocardial
ischemia–reperfusion injury, and simultaneous inhibition
of necroptosis and apoptosis enhances the cardioprotective
effect. These findings may provide a novel, additive strat-
egy for cardioprotection in acute myocardial infarction.
Keywords Necroptosis  Necrostatin-1  Ischemia–
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Introduction
Acute myocardial infarction remains a life-threatening
complication during the perioperative period. Cardiomyo-
cyte death in ischemia–reperfusion injury has been con-
sidered to be an accidental cell death resulting from
excessive stress that is mainly caused by necrosis. In
contrast to this unexpected death, programmed cell death,
apoptosis, also has been shown to be involved in myocar-
dial ischemia–reperfusion injury [1–3]. It is a highly reg-
ulated mechanism designed to eliminate cells via caspase
activation to maintain homeostasis [4]. Stimulation of the
death receptors such as Fas and tumor necrosis factor-a
(TNF-a) receptors normally leads to the activation of
the extrinsic apoptotic pathway. However, it has been
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demonstrated that death-receptor stimulation could still
induce cell death with morphological features of necrosis
in some cell types when the canonical apoptotic pathway is
blocked [5], which implies the existence of regulated
necrosis. Recently, as an alternative death pathway, cas-
pase-independent programmed necrosis has been identified
by Degterev et al. [6] and termed necroptosis. In this
pathway, the serine/threonine kinase activity of receptor-
interacting protein 1 (RIP1) plays an important role in cell
death, and its inhibitor, necrostatin-1, has also been iden-
tified [7, 8]. Necrostatin-1 is a small tryptophan-based
molecule that has been shown to reduce infarct volume
after middle cerebral artery occlusion following intracere-
broventricular injection [6] and to block TNF-a-induced
necrotic cell death through inhibition of RIP1 kinase
activity in Jurkat cells [9]. This drug was also reported to
protect the heart against ischemia–reperfusion injury [10].
Furthermore, Wang et al. [11] demonstrated that necrost-
atin-1 also suppresses apoptosis in mice traumatic brain
injury. These findings suggest that necrostatin-1 could
represent a potential therapeutic intervention against acute
myocardial infarction. As several different pathways have
been reported to be involved in myocardial ischemia–
reperfusion injury, a combination therapy may be required
for more efficient cardioprotection. Hence, we examined
whether necroptosis is involved in myocardial ischemia–
reperfusion injury in isolated guinea pig hearts and whether
simultaneous inhibition of necroptosis and apoptosis by
necrostatin-1 and Z-VAD-fmk (an apoptosis inhibitor)
confers an enhanced cardioprotection. Elucidating the
involvement of necroptosis in myocardial ischemia–reper-
fusion injury could lead to a novel, additional strategy for
cardioprotection in the perioperative period.
Materials and methods
This study was conducted in accordance with the Guide-
lines for Animals Research at Osaka Dental University, and
with the approval of the Animal Experiment Committee of
Osaka Dental University, Osaka, Japan. These guidelines
conform to those laid out in the Guide for the Care and Use
of Laboratory Animals, available from the National
Academy of Science. Male Hartley guinea pigs were fed
Lab Diet (RC4; Oriental Yeast, Tokyo, Japan) and given
water ad libitum. Necrostatin-1 was purchased from Cal-
biochem (La Jolla, CA, USA) and was used to inhibit
necroptosis. Z-VAD-fmk was purchased from Peptide
Institute (Osaka, Japan) and was used to inhibit apoptosis.
Necrostatin-1 and Z-VAD were dissolved in dimethyl
sulfoxide (DMSO) and added to Krebs–Henseleit perfusate
to give final concentrations of 10 and 0.1 lM, respectively,
and not more than 0.01 % DMSO.
Isolated heart perfusion and measurement of function
Male guinea pigs weighing 550–800 g (12–14 weeks old)
were given heparin (1,000 U intraperitoneally), then
anesthetized with pentobarbital (60 mg/kg, intraperitone-
ally). Hearts were excised and immediately arrested in cold
iso-osmotic saline containing 20 mM KCl. The aorta was
cannulated and the isolated hearts were perfused at
70 mmHg on a nonrecirculating isovolumic perfused heart
apparatus, using a Krebs–Henseleit (KH) perfusate:
118 mM NaCl, 4.0 mM KCl, 2.52 mM CaCl2, 24.8 mM
NaHCO3, 1.7 mM MgSO4, 1.2 mM KH2PO4, 11.0 mM
glucose, 0.5 mM EDTA, and 8 U/l insulin. The perfusate
was insufflated continuously with 95 % O2/5 % CO2 and
was filtered through cellulose acetate membranes with a
pore size of 4.0 lm to remove particulate matter. Hearts
were paced at 240 beats/min using platinum-tipped elec-
trodes connected to a Grass Instruments SD-5 stimulus
generator (Grass Instruments, Quincy, MA, USA). Left
ventricular developed pressure (LVDP, mmHg) was mea-
sured using a 2.5-French, high-fidelity micromanometer
(Nihon-Kohden, Tokyo, Japan) passed into a compliant
latex balloon, inserted into the left ventricle, and recorded
on a PowerLab 2/20 Data Recording System (ADInstru-
ments, Hayward, Australia). The balloon was connected to
a Y-adapter with one end used to advance the microma-
nometer and the other used to fill the left ventricular bal-
loon with bubble-free water to an end-diastolic pressure
(LVEDP) of 10 mmHg. Coronary flow (CF) was measured
by collecting effluent (ml/min). Global ischemia was
achieved by clamping the aortic inflow line. During
ischemia, hearts were maintained at 37 C by enclosure in
a water-jacketed air chamber. Warmed perfusate kept in
the lower part of the chamber saturated the air with
humidity and prevented cooling by evaporation. Heart
temperature was continuously monitored by a digital
thermometer (PTW-100A, Unique Medical, Tokyo, Japan).
Experimental protocol
Animals were assigned to one of four groups (n = 8 each;
Fig. 1). A schematic illustration of the experimental pro-
tocol of this study is shown in Fig. 1. After a 20-min
equilibration, baseline LVDP, LVEDP, and CF were
recorded. Control hearts were subjected to 30 min of global
ischemia followed by 2 h (for infarct size study) or 4 h (for
Western blot study) of reperfusion. To investigate the
involvement of necroptosis in myocardial ischemia–reper-
fusion injury, necrostatin-1 (necroptosis inhibitor, 10 lM)
was administered starting 5 min before ischemia and dur-
ing the initial 30 min of reperfusion (Nec). The experi-
ments using Z-VAD (apoptosis inhibitor, 0.1 lM) were
done in the same manner. The Nec ? Z-VAD group was
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treated with both inhibitors and was subjected to the
identical protocol.
Determination of myocardial infarct size
After 2 h reperfusion, the hearts were quickly frozen at
-80 C for 15 min, then sliced into 2-mm-thick transverse
sections from apex to base (6 slices/heart). After removing
the right ventricle and defrosting, each slice was weighed
and incubated at 37 C with 1 % triphenyltetrazolium
chloride (TTC; Sigma Chemicals) in phosphate buffer (pH
7.4) for 10 min and then fixed in 10 % formalin for at least
5 h to distinguish red-stained viable tissue from pale
unstained necrotic tissue [12]. Each slice was photographed
and the necrotic area was determined using Adobe Photo-
shop CS (Adobe, San Jose, CA, USA) and multiplied by
the weight of the slice, then expressed as a fraction of the
left ventricle.
Western blot analysis
Separate experiments were performed (n = 4 in each
group) to examine expression of RIP1, pro-caspase 3, and
activated caspase 3. Myocardial tissue samples were col-
lected after 4 h reperfusion and homogenized in ice-cold
homogenizing buffer containing 250 mM sucrose, 20 mM
HEPES (pH 7.5), 10 mM KCl, 2 mM EGTA, 2 mM
MgCl2, 25 mM NaF, 50 mM b-glycerophosphate, 1 mM
Na3VO4, 1 mM PMSF, 1 % Triton X, and protease
inhibitor leupeptin (10 lg/ml). The homogenate was
centrifuged at 1,000 g and 4 C for 5 min. The supernatant
was recentrifuged at 10,000 g and 4 C for 15 min. Protein
concentration was estimated with a Bradford assay.
Equivalent amounts (20 lg) of protein samples were loa-
ded and separated on a 5–10 % sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) gradient
gel, then electrically transferred overnight to a polyvinyl-
idene difluoride membrane (Millipore, Billerica, MA,
USA). After blocking with 5 % skim milk in Tris-buffered
saline containing 0.1 % Tween-20 (TBS-T), the mem-
branes were incubated for 2 h at 4 C in TBS-T containing
5 % milk and overnight 1:500 dilution of rabbit primary
antibody for RIP1, pro-caspase 3, and activated caspase 3
(Santa Cruz Biotechnology, Dallas, TX, USA). Membranes
were then washed three times with TBS-T for 10 min and
subsequently incubated with a 1:1,000 dilution of horse-
radish peroxidase-labeled anti-rabbit immunoglobulin G
(NA 934V; GE Healthcare, Buckinghamshire, UK) in
TBS-T containing 5 % milk. The same blot was stripped
and reblotted with antibodies to b-actin (Santa Cruz
Biotechnology) to confirm equal protein loading. Bound
antibody signals were detected with enhanced chemilumi-
nescence (Pierce Biotechnology, Rockford, IL, USA) and
visualized using a VersaDoc 5000 Imaging System (Bio-
Rad, Hercules, CA, USA). Quantitative analysis of the
band densities was performed by Quantity One software
(Bio-Rad), and the results are presented as the ratio of
RIP1, pro-caspase 3, and activated caspase 3 to b-actin,
respectively. The average light intensity was multiplied by
100 to facilitate presentation of an x-fold increase.
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Fig. 1 Schematic illustration of
the experimental protocol of this
study. All hearts were subjected
to 30 min global ischemia
followed by 120 min
reperfusion. Necrostatin-1
(10 lM, inhibitor of
necroptosis), Z-VAD (0.1 lM,
inhibitor of apoptosis), and both
inhibitors were administered for
5 min before ischemia and
30 min at the onset of
reperfusion. Tissue samples
were obtained at 4 h after
reperfusion. n = 8 for each
group. CTL control, Nec
necrostatin-1, Z-VAD Z-VAD-
fmk
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Statistical analysis
All data are expressed as mean ± SD. Statistical power
analysis revealed that a sample size of n = 8 would pro-
vide sufficient power (0.8) to detect a difference between
mean infarct size indices of 15 % (SD = 9, a = 0.05). A
group size of n = 4 was used for Western blot to provide a
power of 0.8 to detect a difference between means of 20 %
(SD 10, a = 0.05). Hemodynamic data were tested for
normal distribution and subsequently analyzed by a two-
factor repeated-measures analysis of variance (ANOVA)
for time and treatment. If an overall difference between the
variables was observed, comparisons were performed as
one-way ANOVA followed by Tukey’s post hoc test for
intergroup differences and by Dunnett’s for intragroup
differences with baseline values as the reference time
point. Analyses of infarct size and Western blot were
performed using one-way ANOVA followed by Student’s
t test with Bonferroni’s correction for multiple compari-
sons to avoid type I error. For changes within and between
groups, a two-tailed p value less than 0.05 was considered
significant in advance (SPSS17 for Windows, SPSS Japan,
Tokyo, Japan).
Results
Of a total of 56, 4 hearts were not used secondary to
intractable ventricular fibrillation after reperfusion (2 in
CTL, 1 in Nec, and 1 in Z-VAD). There was no significant
difference in body weight among groups.
Hemodynamics
Hemodynamic data are shown in Table 1. Baseline LVDP
and CF were similar among the four groups. Administra-
tion of necrostatin-1 and Z-VAD did not significantly
affect LVDP or CF before ischemia. Recovery of LVDP
was greater in Nec ? Z-VAD compared with the other
three groups (Nec ? Z-VAD: 47 ± 6 vs. CTL: 30 ± 12,
Nec: 41 ± 11, Z-VAD: 43 ± 11 mmHg, p \ 0.05 at
120 min of reperfusion). LVEDP increased significantly in
CTL after ischemia–reperfusion compared with baseline.
The increase in LVEDP was significantly less in Nec ? Z-
VAD compared with CTL during reperfusion period
(28 ± 9 vs. 53 ± 20 mmHg, p \ 0.05 at 120 min of
reperfusion).
There was no significant difference in CF among all
groups throughout the experiment, which suggests that
changes in CF could not account for the improved con-
tractile recovery of Nec ? Z-VAD hearts.
Table 1 Hemodynamic variables
Baseline Reperfusion (min)
30 60 120
LVDP (mmHg)
CTL 111 ± 15 36 ± 13 35 ± 12 30 ± 12
Nec 99 ± 11 48 ± 12 46 ± 11 41 ± 11
Z-VAD 118 ± 15 38 ± 12 41 ± 12 43 ± 11
Nec ? Z-VAD 111 ± 16 50 ± 10 50 ± 7* 47 ± 6*
LVEDP (mmHg)
CTL 10 ± 0 54 ± 18 53 ± 19 53 ± 20
Nec 10 ± 0 45 ± 18 41 ± 18 40 ± 18
Z-VAD 10 ± 0 37 ± 13 32 ± 15 31 ± 16
Nec ? Z-VAD 10 ± 0 33 ± 5* 29 ± 6* 28 ± 9*
CF (ml/min)
CTL 27 ± 8 18 ± 6 16 ± 6 17 ± 7
Nec 29 ± 6 25 ± 7 22 ± 9 21 ± 8
Z-VAD 30 ± 18 26 ± 8 22 ± 9 21 ± 12
Nec ? Z-VAD 25 ± 5 22 ± 10 19 ± 7 17 ± 6
Data are presented as mean ± SD
LVDP left ventricular developed pressure, LVEDP left ventricular
end-diastolic pressure, CF coronary flow, CTL control, Nec necrost-
atin-1, Z-VAD Z-VAD-fmk
* p \ 0.05 vs. CTL, n = 8 for each group
In
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Fig. 2 Infarct size as a percentage of LV in four groups. Infarct size
was significantly reduced in Nec and Z-VAD compared to CTL
(33 ± 10 %, 33 ± 5 % vs. 52 ± 6 %, p \ 0.05). Combination of
necroptosis and apoptosis inhibition further reduced infarct size
(Nec ? Z-VAD; 12 ± 2 % vs. Nec, Z-VAD; p \ 0.05). Data are
presented as mean ± SD. * p \ 0.05 vs. CTL, § p \ 0.05 vs. Nec,
Z-VAD (n = 8 for each group)
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Myocardial infarct size
Myocardial infarct size data are shown in Fig. 2. Myo-
cardial infarct size in Nec and Z-VAD groups was signif-
icantly reduced by 37 % compared with control hearts
(Nec: 33 ± 10 %, Z-VAD: 33 ± 5 % vs. CTL: 52 ± 6 %,
p \ 0.05). Combination of necrostatin-1 and Z-VAD fur-
ther reduced myocardial infarct size in Nec ? Z-VAD
group (12 ± 2 %).
Western blot analysis
The expression of RIP1, pro-caspase 3, and activated cas-
pase 3 at 4 h after reperfusion is illustrated by a repre-
sentative Western blot (Figs. 3a, 4a). Expression of RIP1
was significantly preserved in Z-VAD and Nec ? Z-VAD
compared with CTL (Fig. 3b). This preservation was not
caused by unequal loading of the Western blot, as shown
by the detection of b-actin. The expression of pro-caspase 3
in Z-VAD and Nec ? Z-VAD was better preserved
whereas it was decreased in CTL and Nec, suggesting that
apoptosis was executed in CTL and Nec, and was blocked
in Z-VAD and Nec ? Z-VAD. This was confirmed by
increased expression of activated caspase 3 in CTL
whereas it was attenuated in Z-VAD and Nec ? Z-VAD
(Fig. 4).
Discussion
The present study demonstrated that the caspase-independent
programmed necrosis, necroptosis, may be involved in acute
myocardial ischemia–reperfusion injury in isolated guinea pig
hearts. Further, combination therapy targeting different forms
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Fig. 3 a Representative Western blot of RIP1 from left ventricular
samples acquired at 240 min after reperfusion (n = 4 for each group).
Expression of RIP1 was significantly preserved in Z-VAD and
Nec ? Z-VAD compared with CTL. b Densitometric evaluation of
four experiments as the x-fold increase in average light density (AVI).
The results are presented as the ratio of RIP1 to b-actin. Average light
intensity was multiplied by 100 to facilitate presentation of an x-fold
increase. Data are mean ± SD. * p \ 0.05 vs. CTL,  p \ 0.05 vs.
before ischemia
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Fig. 4 a Representative Western blot of pro-caspase 3 and acti-
vated caspase 3 from left ventricular samples acquired at 4 h min
after reperfusion (n = 4 for each group). Expression of pro-caspase 3
in Z-VAD and Nec ? Z-VAD was better preserved whereas it was
decreased in CTL. Expression of activated caspase 3 was significantly
increased in CTL and was slightly increased in Nec. b Densitometric
evaluation of four experiments as the x-fold increase in average light
density (AVI). Results are presented as the ratio of pro-caspase 3 and
activated caspase 3 to b-actin. The average light intensity was
multiplied by 100 to facilitate presentation of an x-fold increase. Data
are mean ± SD. * p \ 0.05 vs. CTL;  p \ 0.05 vs. before ischemia;
§ p \ 0.05 vs. Nec
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of cell death (necroptosis and apoptosis) confers an enhanced
effect in reducing myocardial infarct size. This effect is
associated with inhibition of RIP1 by necrostatin-1 and cas-
pase 3 by Z-VAD. As ventricular remodeling caused by
apoptotic and non-apoptotic programmed cardiomyocyte
death is an active process that contributes to cardiac dys-
function long after acute myocardial infarction [13], it is an
attractive therapeutic target. This study could provide an
additional therapeutic target to improve left ventricular
recovery after myocardial infarction.
Degterev et al. first reported a caspase-independent
programmed necrosis as an alternative form of regulated
cell death, termed necroptosis. They also identified an
inhibitor of necroptosis, necrostatin-1, screening of a
chemical library of 15,000 compounds, and demonstrating
that intracerebroventricular injection of necrostatin-1 con-
tributed to delayed mouse ischemic brain injury [6]. They
further demonstrated that necrostatin-1 inhibits RIP1
kinase activity, suggesting that RIP1 plays an important
role in necroptosis. Although the effect of necrostatin-1 on
necroptosis was reported in several cell lines such as Jurkat
cells, both in vitro and in vivo data on the use of ne-
crostatin-1 in cardiomyocytes are limited. This is the first
study demonstrating the cardioprotective effects of ne-
crostatin-1 in guinea pig hearts. Smith et al. [10] first
described that necrostatin-1 protects against myocardial
ischemia–reperfusion injury in vitro and in vivo mouse
hearts and in cardiomyocytes isolated from rats. They
reported that administration of necrostatin-1 at 30 lM, but
not 100 lM, for 35 min after reperfusion reduced myo-
cardial infarct size approximately 30 % in isolated mouse
hearts. In the present study, administration of necrostatin-1
at 10 lM for 30 min after reperfusion reduced infarct size
approximately 30 % compared to control, although this
dose of necrostatin-1 is relatively low. Z-VAD-fmk is a
pan-caspase inhibitor that has been shown to reduce
myocardial ischemia–reperfusion injury by attenuating
apoptosis [14]. When the cell dies of apoptosis, RIP1
assembles with Fas-associated death domain, caspase 8,
and RIP3, then active caspase 8 cleaves RIP1 and induces
apoptosis. When caspase 8 is pharmacologically inhibited
(Z-VAD-fmk inhibits both caspase 8 and caspase 3),
apoptosis cannot be initiated, which results in programmed
necrosis as an alternative form of cell death through RIP1
[15]. Necrostatin-1 inhibits this type of cell death by
inhibiting RIP1 kinase activity. If apoptosis is not blocked,
RIP1 is cleaved by caspase 8, leading to reduced expres-
sion of RIP1 after ischemia–reperfusion.
In the present study, the infarct size of the Nec group
was comparable with that of the Z-VAD group, and the
combination of necrostatin-1 and Z-VAD-fmk further
reduced infarct size. These findings suggest that the further
reduction of infarct size in the Nec ? Z-VAD group was
caused by inhibition of necroptosis by necrostatin-1, as
pro-caspases (3 and 8) are pharmacologically inhibited by
Z-VAD. This mechanism was supported by Western blot
analyses. As shown in Fig. 3, expression of RIP1 was
significantly reduced in CTL and Nec after 4 h reperfusion,
suggesting that RIP1 was cleaved by caspase 8 whereas it
remained intact in Z-VAD and Nec ? Z-VAD because of
suppression of apoptosis. Thus, both apoptosis and nec-
roptosis were likely inhibited in the Nec ? Z-VAD group
(Fig. 4). However, we cannot rule out that there might be
another factor affording cardioprotection during combina-
tion therapy (Nec ? Z-VAD). For example, necrostatin-1
has been shown to exert cardioprotective effects against
oxidative stress [16] and to modulate the mitochondrial
permeability transition pore [17], which has been shown to
be a crucial determinant for cardioprotection [18].
Recently, it has been demonstrated that necrostatin-1
attenuates mitochondrial dysfunction after ischemia by
preventing free radical formation [19]. In the present study,
the magnitude of reduction of RIP1 expression in Nec was
only slightly less than in CTL. This finding suggests that
necrostatin-1 itself could also suppress apoptosis, which is
consistent with the recent study by Wang et al., who
demonstrated attenuation of apoptosis by necrostatin-1 in
traumatic brain injury [11]. Therefore, the finding of the
present study demonstrating that treatment with necrosta-
tin-1 alone reduced infarct size does not necessarily mean
only reduction of necroptosis by necrostatin-1, but may
also be in part the result of attenuation of apoptosis by
necrostatin-1. One study found that RIP1 may be involved
in mediating either apoptosis or necroptosis, depending on
the cellular context. The partial protection against TNF-a-
induced cell death by Z-VAD-fmk in Jurkat cells is further
enhanced by RIP1 inhibition [20].
The following study limitations should be acknowl-
edged. First, although RIP1 is regulated by caspase 8, we
examined expression of caspase 3 to assess apoptosis
because it is an effector caspase (Z-VAD is a pan-caspase
inhibitor). Second, the dose (0.1 lM) of Z-VAD used in
the present study was relatively low. However, Mocanu
et al. [21] demonstrated that 0.1 lM Z-VAD effectively
reduced infarct size by 36 % (similar to the present study)
in isolated rat hearts. Of note, if the apoptotic pathway is
not completely blocked by this concentration of Z-VAD,
we cannot absolutely rule out that the enhanced reduction
in infarct size by the combination of Z-VAD and necrost-
atin-1 could be in part caused by suppression of apoptosis
by necrostatin-1. Third, we determined infarct size at 2 h
after reperfusion whereas myocardial samples for Western
blot were obtained at 4 h after reperfusion. It has been
shown that a reperfusion period of at least 60 min is
required to determine myocardial infarct size by TTC
staining [22]. We extended the reperfusion period to 2 h to
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ensure washout of pyridine nucleotides from necrotic cells,
which interact with TTC. Apoptosis was reported to be
detectable after approximately 4 h after myocardial ische-
mia in previous studies [23, 24]. Fourth, necrostatin-1 was
administered starting 5 min before ischemia and for an
initial 30 min after reperfusion. Although it has been
established that necrostatin-1 exerts a cytoprotective effect
by inhibiting RIP1 kinase activity, other effects such as
effects on free radical formation and mitochondria were not
known. Necrostatin-1 has been shown to prevent free
radical formation [19]. As a burst-free radical formation
occurs during a very early reperfusion period, we targeted
this period to test the infarct size-limiting effects of ne-
crostatin-1 as well as inhibiting RIP1. However, it remains
to be elucidated whether administration of necrostatin-1
throughout the reperfusion period further reduces infarct
size. Further studies are needed.
Conclusions
This study suggests that a combination of anti-necroptosis
and anti-apoptotic therapy is a promising novel strategy for
cardioprotection after ischemia–reperfusion injury.
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